Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media

NEXT STORY
Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG
PREV STORY
Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Galena Biopharma Presented Two Posters at the San Antonio Breast Cancer Symposium

NeuVax™ (nelipepimut-S) Phase 2 VADIS trial design in women with ductal carcinoma in situ ...

author_avatar
NASDAQ Market News

New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM

TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today announced ...

author_avatar
NASDAQ Market News

XBiotech Announces On-Time Submission to the EMA

AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that ...

author_avatar
NASDAQ Market News